Turn this list into pipeline.
Pharmaceutical Companies in Bournemouth: 39 Active Firms (2026)
Pharmaceutical companies develop, manufacture, import or distribute medicines, with this cohort based in and around Bournemouth.
Buying centres cluster around quality assurance, regulatory affairs, supply-chain management and commercial teams serving healthcare, life-sciences, clinical and specialist medicine channels. The likely buyers are business-to-business and public-sector adjacent rather than consumer-led: wholesalers, clinical service providers, medicines suppliers and healthcare organisations that need licensed production, import, assembly, distribution or commercialisation support. Engagements appear operational and narrowly scoped, with small to lower-mid-market suppliers handling defined medicine workflows, licence-dependent processes and repeat supply-chain relationships from Bournemouth or its surrounding metropolitan area.
Read more
Within Bournemouth, 39 pharmaceutical companies are actively trading in this cohort, so the local market reads as a small specialist base rather than a broad manufacturing cluster. Reported employment stands at 67 people across reporting firms, pointing to limited operating scale and a concentration of tightly staffed businesses. The profile fits suppliers that support defined regulated workflows, including import, wholesale distribution, assembly and medicines commercialisation, where compliance capability matters as much as sales reach.
UK human medicines activity sits under MHRA oversight: manufacturing, assembly and import require a manufacturer’s licence, compliance with good manufacturing practice and regular site inspections. Wholesale supply to anyone other than the patient requires a wholesale distribution licence and good distribution practice compliance. Medicines also need marketing authorisation, while health-service access is shaped by cost-effectiveness review. ABPI’s role as the research-based pharmaceutical trade body matters here because even small Bournemouth operators work within national rulebooks rather than a local light-touch regime.
The Bournemouth cohort appears likely to remain weighted towards specialist supply, import, distribution and commercial support rather than large campus research or volume manufacturing. Firms with defensible quality systems, repeat healthcare relationships and licence-management capability tend to have the clearest path to durability. New entrants may stay niche unless they can carry compliance overhead through dependable supply contracts. Consolidation pressure is more likely to sit around distribution rights, inspection readiness and quality assurance infrastructure than around consumer-facing brand reach.
39
Active firms
2026
10
Recent incorporations
Incorporated since 2022
0
Above £5M
Turnover band
Key facts
25% of the cohort was incorporated since 2022 (10 firms), so a sizeable share is in its first few filing cycles.
The MHRA regulates UK human medicines, including standards, clinical trial approvals, medicine licensing and pharmacovigilance.
Organisations that make, assemble or import human medicines need an MHRA manufacturer’s licence, good manufacturing practice compliance and regular site inspections.
Wholesale supply to anyone other than the patient requires a wholesale distribution licence and good distribution practice compliance.
UK businesses performed £9.0 billion of pharmaceutical R&D in 2022, equal to 0.36% of GDP and 18% of all UK business R&D.
UK pharmaceutical exports were valued at £25.6 billion in 2023, ranking tenth among comparator countries.
Top Bournemouth Pharmaceutical companies
Kestrel Medical Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDistributes medical devices and pharmaceutical products, including the Otovent device for treatment of glue ear and Otinova ear care products, on behalf of manufacturers. Also owns and markets the…
Serves a mix of B2B and B2C customers, including UK healthcare professionals, medical stockists and pharmacies, plus patients and parents seeking glue ear and throat care products.
Financial Health
HealthyHealthy · -3% CAGR over 4y
Location
Arrowedge Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable · -6% CAGR over 4y
Location
HOCL LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak
Location
OUR FOCUS LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StableStable · -90% CAGR over 2y
Location
A.T. MEDICAL LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
Johnson L Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures pharmaceuticals and medical technologies, including medicines for oncology, immunology, neuroscience and cardiopulmonary conditions, and medical devices used in…
Serves healthcare providers and patients globally, including hospitals, surgeons and clinicians using medical devices, and patient populations treated in oncology, immunology, neuroscience and…
Financial Health
StrongStrong · Growing, Hiring · 19% CAGR over 4y
Location
Alltrista
Manufactures rigid plastic packaging and custom injection‑moulded products for pharmaceutical, consumer health, and industrial applications, including medicine bottles, dosage cups, child‑resistant…
Sells B2B to pharmaceutical, consumer health and industrial companies needing rigid packaging, custom molded parts and contract manufacturing. Targets product teams and procurement buyers serving…
Location
BIOSIRIUS LTD
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StableStable · 0% CAGR over 2y
Location
CKS Scientific Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
HealthyHealthy · 0% CAGR over 4y
Location
Kensington International Marketing Company Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsActs as an international master distributor for manufacturers and brand owners, managing cross‑border distribution and market development of pharmaceuticals, OTC products, personal care, household…
Serves B2B manufacturers and brand owners in pharmaceuticals, OTC, personal care, household, food and beverages seeking distribution and retail access across Africa, the Middle East, Europe, Asia,…
Financial Health
StableStable · -10% CAGR over 4y
Location
Pharmora Limited
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsProvides medical review and scientific consulting services to pharmaceutical and biotechnology companies, supporting clinical development, pharmacovigilance, regulatory submissions, and medical…
Serves medium and large global pharmaceutical companies, small biotech firms, life sciences investors, and regulatory agencies involved in medical product development, approval, commercialisation and…
Financial Health
StrongStrong · Growing, Hiring · 34% CAGR over 2y
Location
Unlock all 39 leads
Showing 11 of 39 — +28 more with verified decision-maker contacts, live data, and CRM sync.
How Bournemouth Pharmaceutical companies work and how to sell to them
What they do
Bournemouth pharmaceutical operators typically earn revenue from licence-dependent supply and support work rather than consumer-facing brand sales. Common models include wholesale margins, repeat supply contracts, import or assembly fees, regulatory support retainers and project work tied to medicine commercialisation. Pricing is usually operational: per order, per batch, per shipment, per service line or under a recurring agreement with defined quality and documentation obligations. Engagements tend to be modest but sticky where the supplier is embedded in good manufacturing practice, good distribution practice or marketing-authorisation workflows, because switching provider can create audit, continuity and licence-risk issues for the buyer.
Who they sell to
Typical buyers sit in healthcare, life sciences, specialist medicine supply, clinical services and wholesale channels. Decision-makers are often quality assurance leads, regulatory affairs managers, procurement teams, supply-chain managers and finance directors, with pharmacists or clinical operations teams influencing where the product or service affects patient supply. Smaller buyers may purchase through direct relationships and repeat ordering, while larger healthcare or public-sector-adjacent organisations tend to require supplier qualification, quality questionnaires and formal procurement steps. Sales cycles are usually longer where site audits, licence checks, technical agreements or product documentation must be reviewed before work starts.
What they buy
Spending tends to follow the regulated workflow: quality-management systems, document control, audit preparation, supplier qualification, inventory and warehouse tooling, traceability, finance systems and regulatory affairs support. Firms involved in import, assembly or wholesale distribution may also buy logistics services, temperature-monitoring equipment, insurance, legal advice, accounting support and specialist recruitment for quality, regulatory and supply-chain roles. Most smaller pharmaceutical firms are unlikely to buy large enterprise platforms early; they tend to favour tools and services that reduce manual documentation, help pass inspections, maintain licence conditions and keep repeat supply relationships credible with healthcare and wholesale buyers.
Why and how to sell to them
Commercial intent often appears when pharmaceutical firms prepare for an MHRA inspection, apply for or vary a licence, add a new supply route, take on a distribution right, change quality leadership or move from ad hoc work into repeat contracts. Pain points are usually practical: documentation burden, audit readiness, supplier qualification, batch or shipment traceability, and the cost of maintaining compliance with limited staff. Outbound messages tend to land better when they refer to inspection readiness, continuity of medicine supply, reduced manual administration and clearer evidence trails, rather than generic growth claims or broad digital efficiency language.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Bournemouth
Related directories
Frequently asked questions
How many pharmaceutical companies are there in Bournemouth?
What counts as a pharmaceutical company in this list?
Which are the largest pharmaceutical companies in Bournemouth?
What do pharmaceutical companies in Bournemouth actually do?
How does Bournemouth pharmaceutical compare internationally?
How is this list built and how fresh is the data?
How big are the typical pharmaceutical companies in Bournemouth?
Are these mostly new or established pharmaceutical companies?
What SIC codes does this use?
What buying signals should I look for?
Push these 39 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.